News
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...
Summit Therapeutics' potential pipeline could help drive strong stock performances for a long time. Is it worth it to buy a ...
Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...
The Manila Times on MSN2h
AstraZeneca eyes licensing lung cancer drugASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...
The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...
The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...
The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.
Serendipity Space, a pioneering space-tech company developing microgravity-based pharmaceutical manufacturing solutions, has raised its pre-seed round from Campus Fund. The investment will accelerate ...
Key Takeaways The S&P 500 added 0.8% on Thursday, July 3, 2025, reaching a record closing high as a strong jobs report helped ...
Zacks Investment Research on MSN5h
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...
Merck’s stock fell 1.77% to $80.93 while the market gained, despite rising 5.26% over the past month. The company’s upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback